{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:28:50Z","timestamp":1773786530585,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.critrevonc.2025.105074","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:07:41Z","timestamp":1765210061000},"page":"105074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["High-grade gastro-entero-pancreatic neuroendocrine neoplasms: An overlooked population in interventional clinical trials. A systematic review"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-7684","authenticated-orcid":false,"given":"Elettra","family":"Merola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pina","family":"Dore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Mario","family":"Pes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Fanciulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.critrevonc.2025.105074_bib1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00428-006-0250-1","article-title":"TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system","volume":"449","author":"Rindi","year":"2006","journal-title":"Virchows Arch."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105074_bib2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00428-007-0452-1","article-title":"TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system","volume":"451","author":"Rindi","year":"2007","journal-title":"Virchows Arch."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105074_bib3","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1210\/jc.2016-3732","article-title":"Functional imaging in the follow-up of enteropancreatic neuroendocrine tumors: clinical usefulness and indications","volume":"102","author":"Merola","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2025.105074_bib4","series-title":"WHO Classification of Tumours of Endocrine Organs","author":"G K","year":"2017"},{"key":"10.1016\/j.critrevonc.2025.105074_bib5","unstructured":"WHO classification of Tumors Editorial Board: Digestive system tumors. 5th ed; 2019."},{"key":"10.1016\/j.critrevonc.2025.105074_bib6","unstructured":"WHO classification of endocrine and neuroendocrine tumours Lyon, France: IARC.; 2022."},{"key":"10.1016\/j.critrevonc.2025.105074_bib7","unstructured":"WHO Classification of Tumours Endocrine and Neuroendocrine Tumours. 5th ed: International Agency for Research on Cancer (IARC); 2023."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105074_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-21-0152","article-title":"The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"29","author":"Venizelos","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105074_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13249","article-title":"European neuroendocrine tumor society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma","volume":"35","author":"Sorbye","year":"2023","journal-title":"J. Neuroendocr."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105074_bib10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41416-025-03054-w","article-title":"Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study","volume":"133","author":"Sorbye","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105074_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/jne.70080","article-title":"Controversies in NEN: an ENETS position statement on the treatment of patients with Grade 3 well-differentiated neuroendocrine tumours of the gastro-enteropancreatic tract","author":"McNamara","year":"2025","journal-title":"J. Neuroendocr."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105074_bib12","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/cncr.31124","article-title":"Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases","volume":"124","author":"Dasari","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105074_bib13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.critrevonc.2025.105074_bib14","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2025.105074_bib15","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2025.105074_bib16","series-title":"Cochrane Methods","article-title":"A revised tool for assessing risk of bias in randomized trials","author":"Higgins","year":"2016"},{"key":"10.1016\/j.critrevonc.2025.105074_bib17","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105074_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105074_bib19","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1001\/jamaoncol.2022.3395","article-title":"Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial","volume":"8","author":"Morizane","year":"2022","journal-title":"JAMA Oncol."},{"issue":"9(9","key":"10.1016\/j.critrevonc.2025.105074_bib20","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/cncr.32750","article-title":"Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: a randomized phase 2 study","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105074_bib21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/COC.0000000000000668","article-title":"Capecitabine, oxaliplatin, irinotecan, and bevacizumab combination followed by pazopanib plus capecitabine maintenance for high-grade gastrointestinal neuroendocrine carcinomas","volume":"43","author":"Alifieris","year":"2020","journal-title":"Am. J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.105074_bib22","doi-asserted-by":"crossref","first-page":"25669","DOI":"10.18632\/oncotarget.12900","article-title":"Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.105074_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102015","article-title":"NET-02: a randomised, non-comparative, phase II trial of nal-IRI\/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma","volume":"60","author":"McNamara","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105074_bib24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(23)00001-3","article-title":"Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial","volume":"24","author":"Walter","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.105074_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114129","article-title":"A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas","volume":"208","author":"Bongiovanni","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105074_bib26","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/cas.14811","article-title":"Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma","volume":"112","author":"Kobayashi","year":"2021","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105074_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103003","article-title":"A new schedule of one week on\/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial","volume":"9","author":"von Arx","year":"2024","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105074_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100119","article-title":"Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study","volume":"6","author":"Jeong","year":"2021","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105074_bib29","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00280-006-0306-6","article-title":"Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?","volume":"59","author":"Bajetta","year":"2007","journal-title":"Cancer Chemother. Pharm."},{"issue":"11-12","key":"10.1016\/j.critrevonc.2025.105074_bib30","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1159\/000505550","article-title":"A phase II trial of everolimus in patients with advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy (NECTOR Trial)","volume":"110","author":"Okuyama","year":"2020","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.critrevonc.2025.105074_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221077088","article-title":"First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial","volume":"14","author":"Levy","year":"2022","journal-title":"Ther. Adv. Med Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105074_bib32","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1038\/s41416-023-02462-0","article-title":"Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"129","author":"Morken","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105074_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000487237","article-title":"Clinical and biomarker evaluations of sunitinib in patients with grade 3 digestive neuroendocrine neoplasms","volume":"107","author":"Pellat","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.critrevonc.2025.105074_bib34","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105074_bib35","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s00262-020-02811-5","article-title":"Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms","volume":"70","author":"MacFarlane","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105074_bib36","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41416-020-0775-0","article-title":"Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials","volume":"122","author":"Vijayvergia","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105074_bib37","doi-asserted-by":"crossref","first-page":"e782","DOI":"10.1634\/theoncologist.2019-0490","article-title":"An open-label, single-arm, two-stage, multicenter, phase ii study to evaluate the efficacy of TLC388 and genomic analysis for poorly differentiated neuroendocrine carcinomas","volume":"25","author":"Chen","year":"2020","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105074_bib38","doi-asserted-by":"crossref","first-page":"e625","DOI":"10.1093\/oncolo\/oyac097","article-title":"Sintilimab in patients with previously treated metastatic neuroendocrine neoplasms","volume":"27","author":"Jia","year":"2022","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105074_bib39","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/1078-0432.CCR-24-2461","article-title":"Activity and safety of avelumab in high-grade neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas progressive after chemotherapy (AveNEC Trial)","volume":"31","author":"Fottner","year":"2025","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.105074_bib40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2022.03.029","article-title":"Avelumab in unresectable\/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials","volume":"169","author":"Chan","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105074_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103249","article-title":"Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II study","volume":"84","author":"Zhang","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105074_bib42","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1038\/s41467-023-38611-5","article-title":"Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin","volume":"14","author":"Capdevila","year":"2023","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105074_bib43","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.105074_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113539","article-title":"Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: an open-label, single-arm, multi-cohort phase II trial","volume":"199","author":"Zhang","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105074_bib45","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1038\/s41467-024-50969-8","article-title":"Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: the multicenter phase 2 NICE-NEC trial (GETNE-T1913)","volume":"15","author":"Riesco-Martinez","year":"2024","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105074_bib46","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s43018-025-00916-3","article-title":"Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis","volume":"6","author":"Cousin","year":"2025","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105074_bib47","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:36:35Z","timestamp":1770035795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":47,"alternative-id":["S1040842825004627"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105074","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-grade gastro-entero-pancreatic neuroendocrine neoplasms: An overlooked population in interventional clinical trials. A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105074"}}